Rebif Ready For Antegren Following MS Market Share Gains, Serono Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Serono is confident that Rebif can compete against Elan/Biogen Idec's Antegren both on mechanism of action and indication; Antegren's estimated user fee deadline is in November. Rebif gains share against Biogen Idec's Avonex and Berlex' Betaseron, reaching 12-month rolling sales of $1 bil.